Patents by Inventor Fred D. Finkelman

Fred D. Finkelman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190076445
    Abstract: A method of treating a subject suffering from an allergic disorder is provided, the method including inducing rapid desensitization to an allergen, the rapid desensitization effectuated by: administering to the subject a plurality of equal doses of a first anti-Fc?RI? monoclonal antibody, wherein the plurality of equal doses are administered over a 6 to 8 hour period and wherein each dose is lower than a level required to induce shock, thereby inducing rapid desensitization to the allergen. Monoclonal antibodies and methods of co-administering or consecutively administering a combination thereof to effectuate rapid desensitization are also provided.
    Type: Application
    Filed: September 25, 2018
    Publication date: March 14, 2019
    Inventors: Fred D. Finkelman, Marat V. Khodoun, Suzanne C. Morris
  • Patent number: 10086005
    Abstract: A method of treating a subject suffering from an allergic disorder is provided, the method including inducing rapid desensitization to an allergen, the rapid desensitization effectuated by: administering to the subject a plurality of equal doses of a first anti-Fc?RI? monoclonal antibody, wherein the plurality of equal doses are administered over a 6 to 8 hour period and wherein each dose is lower than a level required to induce shock, thereby inducing rapid desensitization to the allergen. Monoclonal antibodies and methods of co-administering or consecutively administering a combination thereof to effectuate rapid desensitization are also provided.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: October 2, 2018
    Inventors: Fred D. Finkelman, Marat V. Khodoun, Suzanne C. Morris
  • Publication number: 20180092929
    Abstract: A method of treating a subject suffering from an allergic disorder is provided, the method including inducing rapid desensitization to an allergen, the rapid desensitization effectuated by: administering to the subject a plurality of equal doses of a first anti-Fc?RI? monoclonal antibody, wherein the plurality of equal doses are administered over a 6 to 8 hour period and wherein each dose is lower than a level required to induce shock, thereby inducing rapid desensitization to the allergen. Monoclonal antibodies and methods of co-administering or consecutively administering a combination thereof to effectuate rapid desensitization are also provided.
    Type: Application
    Filed: December 8, 2017
    Publication date: April 5, 2018
    Inventors: Fred D. Finkelman, Marat V. Khodoun, Suzanne C. Morris
  • Patent number: 9868786
    Abstract: Provided are methods for suppressing IgE and IgG-mediated allergic reactions through monoclonal antibody applications. More specifically, methods are herein provided for safe induction of rapid desensitization. Specific embodiments are herein provided for suppressing allergic reactions in a subject, including specific methods of providing a monoclonal antibody selected from the group consisting of anti-Fc?RIa and anti-Fc?RIIb / RIII; administering the antibody to a subject at a dose that is lower than the level required to induce shock; and administering sequentially escalating doses of the monoclonal antibody so as to induce rapid desensitization to an allergen, thereby suppressing allergic reaction in the subject.
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: January 16, 2018
    Assignees: University of Cincinnati, Children's Hospital Medical Center, U.S. Department of Veterans Affairs, Medizinische Universität Wien
    Inventors: Fred D. Finkelman, Marat V. Khodoun, Durga Krishnamurthy, Richard T. Strait, Zeynep (Yesim) Kucuk
  • Publication number: 20180000837
    Abstract: Methods for suppressing IgE-mediated anaphylaxis are provided herein, which include administering to a person in need thereof a combination of at least two therapeutic agents selected from the group consisting of an antihistamine, one or more beta-adrenergic agonists, and one or more tyrosine kinase antagonists. Also provided herein are methods of suppressing IgE-mediated anaphylaxis associated with immunotherapeutic desensitization of a subject, and pharmaceutical compositions for suppressing IgE-mediated anaphylaxis.
    Type: Application
    Filed: September 14, 2017
    Publication date: January 4, 2018
    Inventors: Fred D. Finkelman, Marat V. Khodoun, Suzanne C. Morris
  • Patent number: 9795618
    Abstract: Methods for suppressing IgE-mediated anaphylaxis are provided herein, which include administering to a person in need thereof a combination of at least two therapeutic agents selected from the group consisting of an antihistamine, one or more beta-adrenergic agonists, and one or more tyrosine kinase antagonists. Also provided herein are methods of suppressing IgE-mediated anaphylaxis associated with immunotherapeutic desensitization of a subject, and pharmaceutical compositions for suppressing IgE-mediated anaphylaxis.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: October 24, 2017
    Assignee: University of Cincinnati
    Inventors: Fred D. Finkelman, Marat V. Khodoun, Suzanne C. Morris
  • Publication number: 20150246125
    Abstract: Methods for suppressing IgE-mediated anaphylaxis are provided herein, which include administering to a person in need thereof a combination of at least two therapeutic agents selected from the group consisting of an antihistamine, one or more beta-adrenergic agonists, and one or more tyrosine kinase antagonists. Also provided herein are methods of suppressing IgE-mediated anaphylaxis associated with immunotherapeutic desensitization of a subject, and pharmaceutical compositions for suppressing IgE-mediated anaphylaxis.
    Type: Application
    Filed: February 27, 2015
    Publication date: September 3, 2015
    Applicant: UNIVERSITY OF CINCINNATI
    Inventors: Fred D. Finkelman, Marat V. Khodoun, Suzanne C. Morris
  • Publication number: 20140314783
    Abstract: Provided are methods for suppressing IgE and IgG-mediated allergic reactions through monoclonal antibody applications. More specifically, methods are herein provided for safe induction of rapid desensitization. Specific embodiments are herein provided for suppressing allergic reactions in a subject, including specific methods of providing a monoclonal antibody selected from the group consisting of anti-Fc?RIa and anti-Fc?RIIb/RIII; administering the antibody to a subject at a dose that is lower than the level required to induce shock; and administering sequentially escalating doses of the monoclonal antibody so as to induce rapid desensitization to an allergen, thereby suppressing allergic reaction in the subject.
    Type: Application
    Filed: April 12, 2012
    Publication date: October 23, 2014
    Inventors: Fred D. Finkelman, Marat V. Khodoun, Durga Krishnamurthy, Richard T. Strait, Zeynep (Yesim) Kucuk
  • Patent number: 6824986
    Abstract: The present invention involves techniques for evaluating in vivo cytokine production through the in vivo capture of secreting cytokines by labeled cytokine-binding reagents, followed by in vitro measurement of serum levels of captured cytokine. The methods of the present invention make use of the ability of a neutralizing antibody to a cytokine, when injected into a person or expierimental animal, to bind that cytokine and prevent its catabolism, excretion, or binding to a cytokine receptor. This causes the cytokine, which may normally have a very short in vivo half life, to accumulate in vivo as a cytokine/anti-cytokine antibody complex. If the anti-cytokine antibody is either labeled with a molecule that can be bound by another molecule (e.g.; biotin, which is bound by avidin or streptavidin), or is itself capable of being bound by another molecule (e.g.
    Type: Grant
    Filed: October 6, 1998
    Date of Patent: November 30, 2004
    Assignee: University of Cincinnati
    Inventors: Fred D. Finkelman, Suzanne C. Morris
  • Patent number: 6063371
    Abstract: The biological activity of exogenous ligand proteins is enhanced by intravenously co-administering to a mammal the ligand and a soluble receptor protein that binds thereto. Pharmaceutical compositions comprising a ligand protein complexed with a soluble receptor protein are provided. In certain embodiments, the ligand is selected from the group consisting of interleukins, colony stimulating factors, and tumor necrosis factor.
    Type: Grant
    Filed: September 16, 1996
    Date of Patent: May 16, 2000
    Assignees: Immunex Corporation, The United States of America as represented by the Secretary of the Army
    Inventors: Charles R. Maliszewski, Fred D. Finkelman
  • Patent number: 4689400
    Abstract: A method is disclosed for the production of antibodies to haptens which comprises binding the hapten to an antibody from one species, injecting the antibody-hapten into another species, and isolating the antibodies produced in response to the hapten.
    Type: Grant
    Filed: June 27, 1985
    Date of Patent: August 25, 1987
    Assignee: The United States of America as represented by the Secretary of the Navy
    Inventor: Fred D. Finkelman